Compare SW & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SW | GMAB |
|---|---|---|
| Founded | 1934 | 1999 |
| Country | Ireland | Denmark |
| Employees | 97000 | 3088 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6B | 16.5B |
| IPO Year | N/A | N/A |
| Metric | SW | GMAB |
|---|---|---|
| Price | $43.32 | $25.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $53.58 | $39.56 |
| AVG Volume (30 Days) | ★ 4.5M | 1.7M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.43 | $17.85 |
| Revenue Next Year | $3.13 | $16.04 |
| P/E Ratio | $38.98 | ★ $1.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.73 | $20.23 |
| 52 Week High | $52.65 | $35.43 |
| Indicator | SW | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 44.45 |
| Support Level | $40.38 | $23.62 |
| Resistance Level | $44.61 | $29.64 |
| Average True Range (ATR) | 1.74 | 0.54 |
| MACD | 0.27 | -0.02 |
| Stochastic Oscillator | 95.60 | 41.62 |
Smurfit WestRock PLC manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. operates a vertically integrated system supplying wood and recovered fiber to produce various grades of board, which are then converted into packaging products. Its main packaging categories include corrugated containers and consumer packaging, with additional products such as solidboard, kraft paper, graphic board, paper sacks, and bag-in-box packaging. The company's geographical segments include North America (including the U.S., Canada and Mexico), Europe, the Middle East and Africa and Asia-Pacific, and Latin America. The majority of the company's revenue is derived from product sales in the North American region.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.